Dr Eliezer Van Allen, Assistant Professor at Harvard Medical School and Medical Oncologist at the Dana Farber Cancer Institute, discusses his groundbreaking work in the genomics of cancer immunotherapy. He highlights how next-generation sequencing (NGS) can identify biomarkers of response and resistance to immunotherapy, and can determine how cancers develop resistance to immune checkpoint blockade.

Explore cancer immunotherapy research and relevant publications here.

View related videos:

• Participant Stratification in Immuno-Oncology Using NGS | Webinar 
• Keeping Pace with Immuno-Oncology Research Breakthroughs and Biomarker Identification 

Subscribe to the Illumina video channel

For Research Use Only. Not for use in diagnostic procedures.